1-(3-chlorophenyl)piperazine has been researched along with Anorexia Nervosa in 4 studies
1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure
1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.
Anorexia Nervosa: An eating disorder that is characterized by the lack or loss of APPETITE, known as ANOREXIA. Other features include excess fear of becoming OVERWEIGHT; BODY IMAGE disturbance; significant WEIGHT LOSS; refusal to maintain minimal normal weight; and AMENORRHEA. This disorder occurs most frequently in adolescent females. (APA, Thesaurus of Psychological Index Terms, 1994)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Neuroendocrine, temperature, test-meal, and psychometric responses are reviewed following challenges with the post-synaptic 5-HT receptor agonist m-chlorophenylpiperazine (m-CPP), the 5-HT precursor L-tryptophan (L-TRP), and placebo in 12 patients with anorexia nervosa (AN) and 16 healthy controls." | 5.08 | Studies of serotonin function in anorexia nervosa. ( Brewerton, TD; Jimerson, DC, 1996) |
| "Although patients with severe migraine-like headaches had higher peak m-CPP levels than patients without severe headaches, these levels are not higher than other groups studied who did not get headaches." | 1.28 | Headache responses following m-chlorophenylpiperazine in bulimics and controls. ( Brandt, HA; Brewerton, TD; Jimerson, DC; Lesem, MD; Murphy, DL, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hadigan, CM | 1 |
| Walsh, BT | 1 |
| Buttinger, C | 1 |
| Hollander, E | 1 |
| Brewerton, TD | 2 |
| Jimerson, DC | 2 |
| Frank, GK | 1 |
| Kaye, WH | 1 |
| Weltzin, TE | 1 |
| Perel, J | 1 |
| Moss, H | 1 |
| McConaha, C | 1 |
| Pollice, C | 1 |
| Murphy, DL | 1 |
| Lesem, MD | 1 |
| Brandt, HA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of cis9,trans11 Conjugated Linoleic Acid on Platelet Function, Markers of Haemostasis and Inflammation on Humans[NCT01234636] | 50 participants (Actual) | Interventional | 2010-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for 1-(3-chlorophenyl)piperazine and Anorexia Nervosa
| Article | Year |
|---|---|
Behavioral and neuroendocrine responses to metaCPP in anorexia nervosa.
Topics: Adult; Affect; Anorexia Nervosa; Arousal; Body Mass Index; Body Weight; Double-Blind Method; Female; | 1995 |
Studies of serotonin function in anorexia nervosa.
Topics: Adolescent; Adult; Anorexia Nervosa; Body Temperature Regulation; Body Weight; Bulimia; Double-Blind | 1996 |
Altered response to meta-chlorophenylpiperazine in anorexia nervosa: support for a persistent alteration of serotonin activity after short-term weight restoration.
Topics: Adolescent; Adult; Affect; Anorexia Nervosa; Body Image; Double-Blind Method; Female; Humans; Pipera | 2001 |
1 other study available for 1-(3-chlorophenyl)piperazine and Anorexia Nervosa
| Article | Year |
|---|---|
Headache responses following m-chlorophenylpiperazine in bulimics and controls.
Topics: Anorexia Nervosa; Bulimia; Female; Humans; Migraine Disorders; Piperazines; Reference Values | 1992 |